JP2023518249A5 - - Google Patents

Info

Publication number
JP2023518249A5
JP2023518249A5 JP2022555959A JP2022555959A JP2023518249A5 JP 2023518249 A5 JP2023518249 A5 JP 2023518249A5 JP 2022555959 A JP2022555959 A JP 2022555959A JP 2022555959 A JP2022555959 A JP 2022555959A JP 2023518249 A5 JP2023518249 A5 JP 2023518249A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
group
hydrogen
independently selected
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022555959A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518249A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/022622 external-priority patent/WO2021188586A1/en
Publication of JP2023518249A publication Critical patent/JP2023518249A/ja
Publication of JP2023518249A5 publication Critical patent/JP2023518249A5/ja
Pending legal-status Critical Current

Links

JP2022555959A 2020-03-16 2021-03-16 ヘキソース型単糖およびその類縁体による、ウイルス感染症の処置方法 Pending JP2023518249A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062990337P 2020-03-16 2020-03-16
US62/990,337 2020-03-16
PCT/US2021/022622 WO2021188586A1 (en) 2020-03-16 2021-03-16 Method of treating viral infections with hexose type monosaccharides and analogs thereof

Publications (2)

Publication Number Publication Date
JP2023518249A JP2023518249A (ja) 2023-04-28
JP2023518249A5 true JP2023518249A5 (cg-RX-API-DMAC10.html) 2024-03-19

Family

ID=75439533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022555959A Pending JP2023518249A (ja) 2020-03-16 2021-03-16 ヘキソース型単糖およびその類縁体による、ウイルス感染症の処置方法

Country Status (11)

Country Link
US (1) US20230130134A1 (cg-RX-API-DMAC10.html)
EP (1) EP4121060A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023518249A (cg-RX-API-DMAC10.html)
KR (1) KR20220166800A (cg-RX-API-DMAC10.html)
CN (1) CN115515601B (cg-RX-API-DMAC10.html)
AU (1) AU2021239927A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022018536A2 (cg-RX-API-DMAC10.html)
CA (1) CA3170872A1 (cg-RX-API-DMAC10.html)
IL (1) IL296389A (cg-RX-API-DMAC10.html)
MX (1) MX2022011488A (cg-RX-API-DMAC10.html)
WO (1) WO2021188586A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118401539A (zh) 2021-12-15 2024-07-26 兆维生物科技公司 官能化的n-乙酰半乳糖胺类似物
US12116382B2 (en) 2022-11-28 2024-10-15 Hongene Biotech Corporation Functionalized N-acetylgalactosamine analogs
EP4582080A1 (en) 2024-01-02 2025-07-09 G.ST Antivirals GmbH Dispenser for mucosal administration comprising 2-deoxy-glucose or analogues thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670330B1 (en) 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
ATE544865T1 (de) * 2002-07-12 2012-02-15 Us Gov Health & Human Serv Assays für den zusammenbau von ebola-virus- nukleocapsiden
AU2004204778B2 (en) 2003-01-10 2008-05-22 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
EP1986660A4 (en) * 2006-02-24 2009-08-26 Univ Texas HEXOSE COMPOUNDS FOR CANCER TREATMENT
WO2009108926A1 (en) 2008-02-29 2009-09-03 Board Of Regents, The University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
WO2008131024A1 (en) 2007-04-17 2008-10-30 Board Of Regents, The University Of Texas System Iodo-hexose compounds useful to treat cancer
US8927506B2 (en) 2008-07-11 2015-01-06 Board Of Regents, The University Of Texas System Acetates of 2-deoxy monosaccharides with anticancer activity
US8173636B2 (en) * 2009-04-03 2012-05-08 Achillion Pharmaceuticals, Inc. Hydroxylthienoquinolones and related compounds as anti-infective agents
WO2012097052A2 (en) * 2011-01-11 2012-07-19 Intertech Bio, Llc Monosaccharide-based compounds for the treatment of proliferative and inflammatory dermatological diseases
EP3517117A1 (en) * 2018-01-30 2019-07-31 Medizinische Universität Wien Medicament for prevention or treatment of rhinovirus infection

Similar Documents

Publication Publication Date Title
JP2021063088A5 (cg-RX-API-DMAC10.html)
KR102318320B1 (ko) 고양이 코로나바이러스 감염의 치료 방법
JP2024170583A5 (cg-RX-API-DMAC10.html)
JP2005526107A5 (cg-RX-API-DMAC10.html)
JP2021100937A5 (cg-RX-API-DMAC10.html)
JP2023002662A5 (cg-RX-API-DMAC10.html)
JP2024516371A5 (cg-RX-API-DMAC10.html)
JP2002501049A5 (cg-RX-API-DMAC10.html)
JP2005533021A5 (cg-RX-API-DMAC10.html)
JP2009538327A5 (cg-RX-API-DMAC10.html)
JP2021102643A5 (cg-RX-API-DMAC10.html)
JP2021521118A5 (cg-RX-API-DMAC10.html)
JP2008534453A5 (cg-RX-API-DMAC10.html)
JP2009521473A5 (cg-RX-API-DMAC10.html)
JP2002528502A5 (cg-RX-API-DMAC10.html)
JP2007520452A5 (cg-RX-API-DMAC10.html)
JP2019533660A5 (cg-RX-API-DMAC10.html)
JPWO2023054732A5 (cg-RX-API-DMAC10.html)
JP2021534160A5 (cg-RX-API-DMAC10.html)
JP2022551691A5 (cg-RX-API-DMAC10.html)
BRPI0610873A2 (pt) tratamento de doenças hepáticas em que o ferro desempenhe um papel na patogênese
TWI894333B (zh) 血管收縮素ii受體拮抗劑代謝產物與nep抑制劑的複合物用於心臟衰竭的應用
JP2022534776A5 (cg-RX-API-DMAC10.html)
JP2002544227A5 (cg-RX-API-DMAC10.html)
BRPI0609258A2 (pt) usos oftálmicos de moduladores do receptor s1p